Objective: It has been demonstrated that quinoline–3–carboxamide, linomide, inhibited angiogenesis and reduced the volume of tumors grown from human hormone–resistant prostate cancer cell lines after subcutaneous implantation in mice. However, subcutaneous xenograft models may not mimic human conditions due to the absence of prostatic stromal cells at the ectopic site. Therefore, we investigated the influence of linomide on local tumor growth and metastasis of the human hormone–resistant prostate cancer cell line PC–3 in an orthotopic model.Methods: In 30 athymic nude mice, 5×105 PC–3 cells were injected into the dorsal prostate after surgical exposure. After 7 days, group 1 (n = 15 mice) received linomide 100 mg/kg/day in the drinking water (per os). The other 15 mice (group 2) served as controls. All mice were sacrified after 38 days followed by macroscopical and histological evaluation of local tumor growth and metastasis. Microvessel density was determined by immunohistochemical staining for von Willebrand factor as well as silver staining followed by morphometric analysis in an area of highest vessel density.Results: In the control group, local tumorigenicity and locoregional lymph node metastasis was 100%. The mean weight of the local tumor was 894 mg (395– 1,261 mg). The mean transversal diameter of the lymph node metastases was 4.0 mm (1.5–5.4 mm). In the treatment group, local tumor growth and lymph node metastasis was 100% with a mean local tumor weight of 869 mg (232–1,131 mg) and a mean lymph node metastasis diameter of 4.6 mm (1.3–5.9 mm). Microvessel density of the local tumor in the control and treatment group did not differ significantly.Conclusion: Contrary to the results reported in subcutaneous animal models, linomide per os has no effect on net tumor growth and metastasis after orthotopic implantation of the human hormone–resistant prostate cancer cell line PC–3 in nude mice.

1.
Huggins C, Hodges CV: Studies in prostate cancer. 1. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–297.
2.
Prostate Cancer Trialists Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265–269.
3.
Oh WK, Kantoff PW: Management of hormone–refractory prostate cancer: Current standards and future prospects. J Urol 1998;160: 1220–1229.
4.
Vogelzang NJ: One hundred thirteen men with hormone–refractory prostate cancer died today. J Clin Oncol 1996;14:1753–1755.
5.
Mani S, Vogelzang NJ: Is ‘off–protocol’ chemotherapy for androgen–independent carcinoma of the prostate warranted? Hematol Oncol Clin North Am 1996;10:749–768.
6.
Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic state in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678–683.
7.
Waku S, Furusato M, Itoh T, Sasaki H, Akiyama A, Inoshita I, Asano K, Tokuda T, Aizawa S, Ushigome S: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J Pathol 1992;168:257–262.
8.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27–31.
9.
Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499–1504.
10.
Vukanovic J, Isaacs JT: Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995;55:3517–3520.
11.
Rembrink K, Romijn JC, van der Kwast TH, Rübben H, Schröder FH: Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for prostate cancer. Prostate 1997;31:168–174.
12.
Bex A, Lümmen G, Rembrink K, Otto T, Metz K, Rübben H: Influence of pertussis toxine on local tumor growth and metastatis after orthotopic implantation of the human prostate cancer cell line PC–3 in nude mice. Prost Cancer Prost Dis 1999;2:36–40.
13.
Kaighn ME, Narayan KS, Ohnuki Y, Lechner J, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC–3). Invest Urol 1979;17:16–23.
14.
Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley–Asp B, Isaacs JT: Anti–angiogenic effects of the quinoline–3–carboxamide linomide. Cancer Res 1993;53:1833–1837.
15.
Lissbrant IF, Stattin P, Damber J–E, Bergh A: Vascular density is a predictor of cancer specific survival in prostatic carcinoma. Prostate 1997;33:38–45.
16.
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.
17.
Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986;5:29–49.
18.
Ware JL, Paulson DF, Mickey GH, Webbs KS: Spontaneous metastasis of cells of the human prostate carcinoma cell line PC–3 in athymic nude mice. J Urol 1982;128:1064–1067.
19.
Thalmann GN, Anezinis PE, Chang S–M, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK: Androgen–independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577–2581.
20.
Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK: Acceleration of human prostate cancer growth in vivo by prostate and bone fibroblasts. Cancer Res 1991;51:3753– 3761.
21.
Chung LWK, Li W, Gleave ME, Hsieh JT, Wu H–C, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, von Eschenbach AC: Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem Suppl 1992;16H:99–105.
22.
Stephenson RA, Dinney CN, Gohji K, Ordonez NG, Killion JJ, Fidler IJ: Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951–957.
23.
Bex A, Geis C, Rembrink K, Grigoleit U, Rübben H: Isolation einer Zellinie DU 145 MN1 nach orthotoper Implantation von DU 145–Zellen in die Prostata der Nacktmaus. Aktuelle Urol 1998;28(suppl):43.
24.
Connolly JM, Sun X–G, Rose DP: A comparison of the expression of the malignant phenotype in two androgen–independent human prostate cancer cell lines after orthotopic implantation in nude mice. Int J Oncol 1997;11: 771–776.
25.
Connolly JM, Rose DP: Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 1998;160:932–936.
26.
Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169–180.
27.
Pollard M: Effects of linomide on advanced prostate–seminal vesicle cancers in Lobund–Wistar rats. Prostate 1998;35:43–49.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.